Q
QED Therapeutics
0 followers
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor ty... Read more
Org chart
Matt Outten
Chief Executive Officer
Matt Outten
Collapse
Upgrade to view 14 reports
Board & advisors
Neil Kumar
Chairman of the Board
Frank McCormick
Board Member